LICENSE AGREEMENTS AND DEFERRED REVENUE	9 Months Ended
Aug. 31, 2011
Disclosure - Deferred Revenue and License Agreements [Abstract]
Deferred Revenue and License Agreements [Text Block]	NOTE 9. LICENSE AGREEMENTS AND DEFERRED REVENUE On October 9, 2007, MultiCell Technologies, Inc. (“MultiCell”) executed an exclusive license and purchase agreement (the “Agreement”) with Corning Incorporated (“Corning”) of Corning, New York. Under the terms of the Agreement, Corning has the right to develop, use, manufacture, and sell MultiCell’s Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (ADME/Tox assays). MultiCell retained and will continue to support all of its existing licensees, including Pfizer and Bristol-Myers Squibb. MultiCell retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. MultiCell also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to produce therapeutic proteins using the Company’s BioFactories™ technology, to identify drug targets and for other applications related to the Company’s internal drug development programs. Corning paid MultiCell $750,000 in consideration for the license granted. The Company is recognizing the income ratably over a 17 year period. The Company recognized $11,029 and $33,088, respectively, in income for the three months and nine months ended August 31, 2011 and 2010. The balance of deferred revenue from this license is $577,206 at August 31, 2011 and will be amortized into revenue through October 2024. The Company had a license agreement with Eisai, for which revenue was being deferred. On May 1, 2009, Eisai notified the Company of its plan to terminate the license agreement effective March 31, 2010. The Company recognized revenue from the agreement with Eisai in the amounts of zero and $49,544 for the three months and the nine months ended August 31, 2010, respectively. The balance of deferred revenue from the agreement with Eisai is zero at August 31, 2011, and no further revenue has been or will be recognized since the termination of the license agreement effective March 31, 2010. The Company has another license agreement with Pfizer, for which revenue is being deferred. The Company recognized revenue from the agreement with Pfizer in the amount of $1,300 and $3,900 for the three months and the nine months ended August 31, 2011 and 2010, respectively. The balance of deferred revenue from the agreement with Pfizer is $32,500 at August 31, 2011, which will be amortized into revenue through January 2018.

NOTE 9. LICENSE AGREEMENTS AND DEFERRED REVENUE

On October 9, 2007, MultiCell Technologies, Inc. (“MultiCell”) executed an exclusive license and purchase agreement (the “Agreement”) with Corning Incorporated (“Corning”) of Corning, New York. Under the terms of the Agreement, Corning has the right to develop, use, manufacture, and sell MultiCell’s Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (ADME/Tox assays). MultiCell retained and will continue to support all of its existing licensees, including Pfizer and Bristol-Myers Squibb. MultiCell retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. MultiCell also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to produce therapeutic proteins using the Company’s BioFactories™ technology, to identify drug targets and for other applications related to the Company’s internal drug development programs. Corning paid MultiCell $750,000 in consideration for the license granted. The Company is recognizing the income ratably over a 17 year period. The Company recognized $11,029 and $33,088, respectively, in income for the three months and nine months ended August 31, 2011 and 2010. The balance of deferred revenue from this license is $577,206 at August 31, 2011 and will be amortized into revenue through October 2024.

The Company had a license agreement with Eisai, for which revenue was being deferred. On May 1, 2009, Eisai notified the Company of its plan to terminate the license agreement effective March 31, 2010. The Company recognized revenue from the agreement with Eisai in the amounts of zero and $49,544 for the three months and the nine months ended August 31, 2010, respectively. The balance of deferred revenue from the agreement with Eisai is zero at August 31, 2011, and no further revenue has been or will be recognized since the termination of the license agreement effective March 31, 2010.

The Company has another license agreement with Pfizer, for which revenue is being deferred. The Company recognized revenue from the agreement with Pfizer in the amount of $1,300 and $3,900 for the three months and the nine months ended August 31, 2011 and 2010, respectively. The balance of deferred revenue from the agreement with Pfizer is $32,500 at August 31, 2011, which will be amortized into revenue through January 2018.